Thomas McCauley, PhD, on Continuing Evaluations on OTX-2002 for MYC-Expressing Cancers

Commentary
Video

The chief scientific officer at Omega Therapeutics discussed milestones Omega Therapeutics is looking forward to in the next year.

This is the fourth part of an interview with Thomas McCauley, PhD. For the third part, click here.

“We're going to trial in the United States, Asia and Europe. Asia is critical here in the sense that, in the US, hepatocellular carcinoma (HCC) is a more rare condition. But globally, and particularly in Asia, HCC is really very prevalent. So, there's a lot of lot of unmet need there in the second line, and even in first line treatment, depending on the region.”

OTX-2002, a MYC-targeted Omega Epigenomic Controller (OEC) therapy developed by Omega Therapeutics, has demonstrated specific, on-target genomic engagement and proof-of-concept in changing the epigenetic state and downregulating expression of c-MYC in patients with hepatocellular carcinoma (HCC) and other solid tumors associated with the c-MYC (MYC) gene in preliminary data from the phase 1/2 MYCHELANGELO-1 trial (NCT05497453).

MYCHELANGELO-1 has treated 4 patients in each of 2 dose level cohorts, receiving either 0.02 mg/kg or 0.05 mg/kg of OTX-2002 monotherapy intravenously every 2 weeks. The second part of the study will assess OTX-2002 in combination therapy. The therapy was well tolerated with no dose-limiting toxicities (DLTs) and the maximum tolerated dose was not reached. Most adverse events (AEs) were grade 1 or 2 (87%) and the most common treatment-related AEs were infusion-related reactions (26%.

CGTLive spoke with Thomas McCauley, PhD, chief scientific officer, Omega Therapeutics, to learn more about OTX-2002. He also discussed milestones Omega is looking forward to in the next year.

REFERENCE
McCauley T. MYCHELANGELO™ I preliminary data overview. Presentation. September 26, 2023. https://ir.omegatherapeutics.com/static-files/19eca20b-260d-4f30-8a13-16b05a5cb26b
Related Videos
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.